MPD2   Click here for help

GtoPdb Ligand ID: 13349

Compound class: Synthetic organic
Comment: MPD2 is a PROTAC degrader of SARS-CoV-2 main protease (Mpro) [1]. It promotes cereblon (CRBN)-mediated, proteasome-driven degradation of the Mpro protein, and has anti-viral efficacy against a range of SARS-CoV-2 strains. Selective Mpro degradation is considered as an alternative pharmacological approach to small molecule inhibitors of protease activity.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 19
Hydrogen bond donors 5
Rotatable bonds 29
Topological polar surface area 253.94
Molecular weight 973.12
XLogP 3.88
No. Lipinski's rules broken 3

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES C[C@H]([C@@H](C(=O)N[C@@H](CC1CCCCC1)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C([H])=O)NC(=O)OCC3=CC=CC(=C3)OCCCCCCOC4=C5C(=CC=C4)C(=O)N(C6CCC(=O)NC6=O)C5=O)OC(C)(C)C
Isomeric SMILES O=C(N[C@@H](C[C@H]1C(NCC1)=O)C([H])=O)[C@H](CC2CCCCC2)NC([C@H]([C@@H](C)OC(C)(C)C)NC(OCC3=CC(OCCCCCCOC4=CC=CC=5C(N(C6CCC(NC6=O)=O)C(C54)=O)=O)=CC=C3)=O)=O
InChI InChI=1S/C51H68N6O13/c1-31(70-51(2,3)4)43(47(63)54-38(27-32-14-8-7-9-15-32)45(61)53-35(29-58)28-34-22-23-52-44(34)60)56-50(66)69-30-33-16-12-17-36(26-33)67-24-10-5-6-11-25-68-40-19-13-18-37-42(40)49(65)57(48(37)64)39-20-21-41(59)55-46(39)62/h12-13,16-19,26,29,31-32,34-35,38-39,43H,5-11,14-15,20-25,27-28,30H2,1-4H3,(H,52,60)(H,53,61)(H,54,63)(H,56,66)(H,55,59,62)/t31-,34+,35+,38+,39?,43+/m1/s1
InChI Key ZKSDAFLRLHGTNH-DTKLLKMQSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Alugubelli YR, Xiao J, Khatua K, Kumar S, Sun L, Ma Y, Ma XR, Vulupala VR, Atla S, Blankenship LR et al.. (2024)
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease.
J Med Chem, 67 (8): 6495-6507. [PMID:38608245]
2. Cao W, Cho CD, Geng ZZ, Shaabani N, Ma XR, Vatansever EC, Alugubelli YR, Ma Y, Chaki SP, Ellenburg WH et al.. (2022)
Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay.
ACS Cent Sci, 8 (2): 192-204. [PMID:35229034]
3. Yang KS, Ma XR, Ma Y, Alugubelli YR, Scott DA, Vatansever EC, Drelich AK, Sankaran B, Geng ZZ, Blankenship LR et al.. (2021)
A Quick Route to Multiple Highly Potent SARS-CoV-2 Main Protease Inhibitors*.
ChemMedChem, 16 (6): 942-948. [PMID:33283984]